Regenerative Medicine Research Center (RMRC), Kermanshah University of Medical Sciences, Kermanshah, Iran.
Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.
Mol Biol Rep. 2023 Oct;50(10):8201-8212. doi: 10.1007/s11033-023-08685-x. Epub 2023 Aug 10.
We aimed to study insertion/deletion (I/D) variation (rs4646994) of ACE gene in a group of SLE patients in west of Iran and its possible relationship with oxidative stress.
Genotypes and allele frequencies related to ACE (I/D) variation were determined in 108 SLE patients and 110 gender and age-matched healthy controls using PCR. Neopterin, malondialdehyde (MDA), and serum lipid concentrations were determined by HPLC and enzyme assay respectively. The overall distribution of ACE I/D genotypes in SLE patients was different from that of the control group (P = 0.005). DD genotype compared to ID genotype increased the risk of SLE (OR = 2.57, 95% CI 1.4-4.8, P = 0.003). ID genotype compared to the II genotype decreased the risk of disease (OR = 0.45, 95% CI 0.2-0.99, p = 0.042). SLE patients with DD, ID, and II genotypes had lower paraoxonase (PON) activity and higher serum levels of MDA and neopterin versus control patients. We also detected a significant protective effect against SLE in presence of ACE I alleles and lack of angiotensin II receptor, type 1 (AGTR1) A1166C (NCBI reference SNP id: rs5186), C alleles in this study (OR = 0.31, 95% CI 0.14-0.68, P = 0.002).
Carriers of the DD genotype of ACE gene with higher serum concentrations of neopterin and MDA, and lower PON activity had a high risk to develop SLE, while ID genotype decreased the risk of disease development by 2.22 times compared to II genotype.
我们旨在研究伊朗西部一组系统性红斑狼疮(SLE)患者 ACE 基因插入/缺失(I/D)变异(rs4646994)及其与氧化应激的可能关系。
采用 PCR 法检测 108 例 SLE 患者和 110 名性别和年龄匹配的健康对照者 ACE(I/D)变异的基因型和等位基因频率。采用 HPLC 和酶法分别测定新蝶呤、丙二醛(MDA)和血清脂质浓度。SLE 患者 ACE I/D 基因型的总体分布与对照组不同(P=0.005)。与 ID 基因型相比,DD 基因型增加了 SLE 的发病风险(OR=2.57,95%CI 1.4-4.8,P=0.003)。与 II 基因型相比,ID 基因型降低了疾病的发病风险(OR=0.45,95%CI 0.2-0.99,P=0.042)。与对照组相比,DD、ID 和 II 基因型的 SLE 患者的对氧磷酶(PON)活性降低,血清 MDA 和新蝶呤水平升高。此外,我们还发现 ACE I 等位基因的存在和缺乏血管紧张素 II 受体 1(AGTR1)A1166C(NCBI 参考 SNP id:rs5186)C 等位基因对 SLE 有显著的保护作用(OR=0.31,95%CI 0.14-0.68,P=0.002)。
携带 ACE 基因 DD 基因型、血清新蝶呤和 MDA 浓度较高、PON 活性较低的患者发生 SLE 的风险较高,而与 II 基因型相比,ID 基因型使疾病发病风险降低 2.22 倍。